{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:58:56Z","timestamp":1767931136934,"version":"3.49.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.josat.2025.209794","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:15:56Z","timestamp":1756192556000},"page":"209794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The effects of psychostimulant prescription on opioid use disorder among people with co-occurring ADHD"],"prefix":"10.1016","volume":"179","author":[{"given":"Mohammad","family":"Yaseliani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngsuhk","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lake","family":"Lindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jabed Al","family":"Faysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Mahmudul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/15504263.2013.867657","article-title":"Stimulant medication for ADHD in opioid maintenance treatment","volume":"10","author":"Abel","year":"2014","journal-title":"Journal of Dual Diagnosis"},{"key":"10.1016\/j.josat.2025.209794_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108493","article-title":"An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals","volume":"177","author":"Al Faysal","year":"2024","journal-title":"Computers in Biology and Medicine"},{"key":"10.1016\/j.josat.2025.209794_bb0015","series-title":"Diagnostic and statistical manual of mental disorders","year":"2022"},{"issue":"2","key":"10.1016\/j.josat.2025.209794_bb0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharmaceutical Statistics"},{"key":"10.1016\/j.josat.2025.209794_bb0025","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jad.2023.07.071","article-title":"The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses","volume":"339","author":"Ayano","year":"2023","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.josat.2025.209794_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115449","article-title":"Prevalence of attention deficit hyperactivity disorder in adults: Umbrella review of evidence generated across the globe","volume":"328","author":"Ayano","year":"2023","journal-title":"Psychiatry Research"},{"issue":"9","key":"10.1016\/j.josat.2025.209794_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093096","article-title":"Challenges of treating ADHD with comorbid substance use disorder: Considerations for the clinician","volume":"12","author":"Barbuti","year":"2023","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.josat.2025.209794_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2025.209794_bb0050","doi-asserted-by":"crossref","DOI":"10.1542\/peds.104.2.e20","article-title":"Pharmacotherapy of attention-deficit\/hyperactivity disorder reduces risk for substance use disorder","volume":"104","author":"Biederman","year":"1999","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.josat.2025.209794_bb0055","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamapsychiatry.2024.3228","article-title":"Diagnosing and treating ADHD in adults: Balancing individual benefits and population risks","volume":"81","author":"Blanco","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.josat.2025.209794_bb0060","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1177\/1087054715626511","article-title":"Comorbidity of adult ADHD and its subtypes with substance use disorder in a large population-based epidemiological study","volume":"23","author":"Capusan","year":"2019","journal-title":"Journal of Attention Disorders"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/10550887.2011.642756","article-title":"Addiction in developmental perspective: Influence of conduct disorder severity, subtype, and attention-deficit hyperactivity disorder on problem severity and comorbidity in adults with opioid dependence","volume":"31","author":"Carpentier","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13722-023-00364-3","article-title":"Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations","volume":"18","author":"Cook","year":"2023","journal-title":"Addiction Science & Clinical Practice"},{"issue":"8","key":"10.1016\/j.josat.2025.209794_bb0075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.883","article-title":"Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users","volume":"22","author":"Darredeau","year":"2007","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"2","key":"10.1016\/j.josat.2025.209794_bb0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1087054711428740","article-title":"An examination of prescription stimulant misuse and psychological variables among sorority and fraternity college populations","volume":"17","author":"Dussault","year":"2013","journal-title":"Journal of Attention Disorders"},{"issue":"6","key":"10.1016\/j.josat.2025.209794_bb0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000484240","article-title":"Attention deficit hyperactivity disorder symptoms are common in patients in opioid maintenance treatment","volume":"23","author":"Fiksdal Abel","year":"2017","journal-title":"European Addiction Research"},{"issue":"2","key":"10.1016\/j.josat.2025.209794_bb0090","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.addbeh.2007.09.008","article-title":"The burden of untreated ADHD among adults: The role of stimulant medication","volume":"33","author":"Goks\u00f8yr","year":"2008","journal-title":"Addictive Behaviors"},{"issue":"5","key":"10.1016\/j.josat.2025.209794_bb0095","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4103\/psychiatry.IndianJPsychiatry_705_19","article-title":"Adult attention-deficit hyperactivity disorders and its correlates in patients with opioid dependence: An exploratory study","volume":"62","author":"Gupta","year":"2020","journal-title":"Indian Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.josat.2025.209794_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0296425","article-title":"Comparing pregnancy and pregnancy outcome rates between adolescents with and without pre-existing mental disorders","volume":"19","author":"Jeon","year":"2024","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.josat.2025.209794_bb0105","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13598","article-title":"Pharmacotherapy for attention-deficit\/hyperactivity disorder and retention in outpatient substance use disorder treatment: A retrospective cohort study","volume":"82","author":"Kast","year":"2021","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.josat.2025.209794_bb0110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.drugalcdep.2009.11.006","article-title":"Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: A pilot study","volume":"108","author":"Konstenius","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209794_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108583","article-title":"Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse","volume":"221","author":"Lagisetty","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"10118","key":"10.1016\/j.josat.2025.209794_bb0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.josat.2025.209794_bb0125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.drugalcdep.2005.06.012","article-title":"Treatment of methadone-maintained patients with adult ADHD: Double-blind comparison of methylphenidate, bupropion and placebo","volume":"81","author":"Levin","year":"2006","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.josat.2025.209794_bb0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamapsychiatry.2015.41","article-title":"Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit\/hyperactivity disorder and cocaine use disorder: A randomized clinical trial","volume":"72","author":"Levin","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.josat.2025.209794_bb0135","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jama.2024.0851","article-title":"ADHD pharmacotherapy and mortality in individuals with ADHD","volume":"331","author":"Li","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2025.209794_bb0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.psychres.2017.01.052","article-title":"Co-occurring attention deficit hyperactivity disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs","volume":"250","author":"Lugoboni","year":"2017","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.josat.2025.209794_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/10550490601082783","article-title":"Treatment strategies for co-occurring ADHD and substance use disorders","volume":"16","author":"Mariani","year":"2007","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.josat.2025.209794_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jsat.2019.05.001","article-title":"Opioid medication discontinuation and risk of adverse opioid-related health care events","volume":"103","author":"Mark","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.josat.2025.209794_bb0155","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/00325481.2017.1354648","article-title":"A clinician\u2019s guide to ADHD treatment options","volume":"129","author":"Mattingly","year":"2017","journal-title":"Postgraduate Medicine"},{"issue":"3","key":"10.1016\/j.josat.2025.209794_bb0160","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ajad.13501","article-title":"Gender differences in the prevalence of stimulant misuse in the United States: 2015\u20132019","volume":"33","author":"McHugh","year":"2024","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.josat.2025.209794_bb0165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpsychires.2022.03.018","article-title":"The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: A systematic review","volume":"149","author":"McKenzie","year":"2022","journal-title":"Journal of Psychiatric Research"},{"issue":"5","key":"10.1016\/j.josat.2025.209794_bb0170","doi-asserted-by":"crossref","first-page":"e2211634","DOI":"10.1001\/jamanetworkopen.2022.11634","article-title":"Analysis of stimulant prescriptions and drug-related poisoning risk among persons receiving buprenorphine treatment for opioid use disorder","volume":"5","author":"Mintz","year":"2022","journal-title":"JAMA Network Open"},{"issue":"7","key":"10.1016\/j.josat.2025.209794_bb0175","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00702-021-02336-w","article-title":"Lifetime evolution of ADHD treatment","volume":"128","author":"Mucci","year":"2021","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0180","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/add.16338","article-title":"Identifying patients with opioid use disorder using International Classification of Diseases (ICD) codes: Challenges and opportunities","volume":"119","author":"Osterhage","year":"2024","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.josat.2025.209794_bb0185","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ps.20220400","article-title":"Trends in attention-deficit hyperactivity disorder diagnosis and pharmacotherapy among adults with opioid use disorder","volume":"75","author":"Park","year":"2024","journal-title":"Psychiatric Services"},{"issue":"9","key":"10.1016\/j.josat.2025.209794_bb0190","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1176\/appi.ajp.2017.16060686","article-title":"ADHD medication and substance-related problems","volume":"174","author":"Quinn","year":"2017","journal-title":"The American Journal of Psychiatry"},{"issue":"8","key":"10.1016\/j.josat.2025.209794_bb0195","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/10600280221141065","article-title":"Gaps in evidence-based treatment of concurrent attention deficit hyperactivity disorder and opioid use disorder: A scoping review","volume":"57","author":"Ramey","year":"2023","journal-title":"The Annals of Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.josat.2025.209794_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20021275","article-title":"Prevalence of attention deficit hyperactivity disorder (ADHD) among substance use disorder (SUD) populations: Meta-analysis","volume":"20","author":"Rohner","year":"2023","journal-title":"International Journal of Environmental Research and Public Health"},{"issue":"3","key":"10.1016\/j.josat.2025.209794_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20032534","article-title":"ADHD prevalence among outpatients with severe opioid use disorder on daily intravenous diamorphine and\/or oral opioid maintenance treatment","volume":"20","author":"Rohner","year":"2023","journal-title":"International Journal of Environmental Research and Public Health"},{"key":"10.1016\/j.josat.2025.209794_bb0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209794_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104434","article-title":"Prevalence of comorbid substance use disorders among people with opioid use disorder: A systematic review & meta-analysis","volume":"128","author":"Santo","year":"2024","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2025.209794_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2022.100122","article-title":"Prescription stimulant use during long-term opioid therapy and risk for opioid use disorder","volume":"5","author":"Scherrer","year":"2022","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"10.1016\/j.josat.2025.209794_bb0225","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.11.04009","article-title":"The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis","volume":"11","author":"Song","year":"2021","journal-title":"Journal of Global Health"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0230","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m11012","article-title":"Opiate antagonists do not interfere with the clinical benefits of stimulants in ADHD: A double-blind, placebo-controlled trial of the mixed opioid receptor antagonist naltrexone","volume":"79","author":"Spencer","year":"2018","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0235","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/npp.2010.160","article-title":"Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: A decade of progress","volume":"36","author":"Swanson","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.josat.2025.209794_bb0240","doi-asserted-by":"crossref","first-page":"e242859","DOI":"10.1001\/jamanetworkopen.2024.2859","article-title":"Attention-deficit\/hyperactivity disorder medications and work disability and mental health outcomes","volume":"7","author":"Taipale","year":"2024","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2023-300728","article-title":"Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: An analysis of treatment retention and overdose risk","volume":"26","author":"Tardelli","year":"2023","journal-title":"BMJ Mental Health"},{"issue":"5","key":"10.1016\/j.josat.2025.209794_bb0250","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11641","article-title":"Stimulant prescription medications among persons receiving buprenorphine for opioid use disorder with prior drug-related poisoning-evidence of net-sum gain","volume":"5","author":"Tsui","year":"2022","journal-title":"JAMA Network Open"},{"issue":"1\u20132","key":"10.1016\/j.josat.2025.209794_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2011.12.007","article-title":"Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis","volume":"122","author":"van Emmerik-van Oortmerssen","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12888-020-02526-y","article-title":"Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; A national prospective cohort study in Norway from 2015 to 2017","volume":"20","author":"Vold","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.josat.2025.209794_bb0265","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2025.209794_bb0270","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1176\/appi.ajp.2021.21070700","article-title":"Association of medication treatment for opioid use disorder with suicide mortality","volume":"179","author":"Watts","year":"2022","journal-title":"The American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.josat.2025.209794_bb0275","doi-asserted-by":"crossref","first-page":"e181152","DOI":"10.1001\/jamanetworkopen.2018.1152","article-title":"Prevalence of and factors associated with long-term concurrent use of stimulants and opioids among adults with attention-deficit\/hyperactivity disorder","volume":"1","author":"Wei","year":"2018","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2025.209794_bb0280","first-page":"21","article-title":"Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature","volume":"47","author":"Wilens","year":"2008","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"4","key":"10.1016\/j.josat.2025.209794_bb0285","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1682","article-title":"ADHD diagnosis and treatment guidelines: A historical perspective","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.josat.2025.209794_bb0290","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14001","article-title":"Association between receipt of antidepressants and retention in buprenorphine treatment for opioid use disorder: A population-based retrospective cohort study","volume":"83","author":"Zhang","year":"2022","journal-title":"The Journal of Clinical Psychiatry"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:29:09Z","timestamp":1767914949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925001730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"alternative-id":["S2949875925001730"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209794","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of psychostimulant prescription on opioid use disorder among people with co-occurring ADHD","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209794"}}